XML 38 R26.htm IDEA: XBRL DOCUMENT v3.24.3
SHARE OPTION PLANS AND ESPP (Tables)
 9 Months Ended
Sep. 30, 2024
Share-Based Payment Arrangement, Recognized Amount [Abstract]  
Schedule of stock option plans
A summary of the status of the Company’s option plans as of September 30, 2024 and changes during the period then ended is presented below:
Nine months ended September 30, 2024
Unaudited
Number
of options		Weighted
average
exercise
price
Outstanding at beginning of year8,539,507 $40.07 
Granted3,797,704 15.88 
Exercised(184,633)7.77 
Forfeited and canceled(719,823)50.14 
Outstanding as of September 30, 202411,432,755 $31.92 
Exercisable options6,804,138 $35.14 
Schedule of RSUs and PSUs
A summary of the status of the Company’s RSUs and PSUs as of September 30, 2024 and changes during the period then ended is presented below.
Nine months ended September 30, 2024
Unaudited
Number
of RSU/PSUs		Weighted
average
grant date fair value
Unvested at beginning of year5,813,066 $60.52 
Granted9,454,291 15.40 
Vested(661,337)84.17 
Forfeited and cancelled(1,252,395)39.97 
Unvested as of September 30, 2024 (1)13,353,625 29.33 

(1) Includes PSUs that have a mix of service, market and other milestone performance vesting conditions which are vested upon achievements of performance milestones that are not probable as of September 30, 2024, in accordance with ASC 718 "Compensation — Stock Compensation" as follows:
 September 30, 2024
Number of
PSUs		Fair value at grant date per PSUTotal fair value at grant date
541,918 $16.30 $8,833 
37,893 19.44 737 
2,703,852 48.16 130,218 
161,422 76.97 12,425 
234,512 80.59 18,899 
15,210 87.66 1,333 
3,694,807 $172,445 
Schedule of fair value assumptions used for All equity based awards estimated using black-scholes option pricing model
The fair value of share-based awards was estimated using the Black-Scholes model for all equity grants. For market condition awards, the Company also applied the Monte-Carlo simulation model. The Company assessed fair value using the following underlying assumptions: 
Nine months ended September 30,Year ended December 31,
2023
20242023
UnauditedAudited
Stock Option Plans
Expected term (years)
5.50-5.73
5.50-6.00
5.50-6.00
Expected volatility
71%-73%
63%-67%
63%-70%
Risk-free interest rate
3.88%-4.43%
3.48%-4.16%
3.48%-4.79%
Dividend yield0.00 %0.00 %0.00 %
ESPP
Expected term (years)0.500.500.50
Expected volatility
73%-90%
56%-122%
56%-122%
Risk-free interest rate
5.13%-5.23%
4.76%-5.38%
4.76%-5.38%
Dividend yield0.00 %0.00 %0.00 %
Schedule of non-cash share-based compensation expense related to company's equity-based awards
The total non-cash share-based compensation expense related to all of the Company’s equity-based awards recognized for the three and nine months ended September 30, 2024 and 2023, and the year ended December 31, 2023 was:
Three months ended September 30,Nine months ended September 30,Year ended December 31,
2023
2024202320242023
UnauditedUnauditedAudited
Cost of revenues$1,834 $1,511 $5,280 $5,540 $6,587 
Research, development and clinical studies7,294 6,683 25,421 26,999 31,827 
Sales and marketing10,276 8,973 31,220 30,830 35,968 
General and administrative11,960 9,179 35,357 34,801 41,226 
Total share-based compensation expense$31,364 $26,346 $97,278 $98,170 $115,608